Table of Contents
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-away
1.5. Stakeholders
2. Executive Summary
2.1. Market definition
2.2. Market segmentation
3. Monoclonal Antibodies Market Insights
3.1. Monoclonal Antibodies – Industry snapshot
3.2. Monoclonal Antibodies - Ecosystem analysis
3.3. Monoclonal Antibodies Market Dynamics
3.3.1. Monoclonal Antibodies – Market Forces
3.3.1.1. Monoclonal Antibodies Market Driver Analysis
3.3.1.2. Monoclonal Antibodies Market Restraint/Challenges analysis
3.3.1.3. Monoclonal Antibodies Market Opportunity Analysis
3.3.2. Industry analysis - Porter's five forces
3.3.2.1. Bargaining power of supplier
3.3.2.2. Bargaining power of buyer
3.3.2.3. Threat of substitute
3.3.2.4. Threat of new entrant
3.3.2.5. Degree of competition
3.3.3. Monoclonal Antibodies Market PEST Analysis, 2017
3.3.4. Monoclonal Antibodies Market Value Chain Analysis
3.3.5. Monoclonal Antibodies Industry Trends
3.3.6. Competitive Ranking Analysis
4. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Product Type
4.1. Key Findings
4.2. Fully Human
4.3. Murine
4.4. Chimeric
4.5. Humanized
5. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Production System
5.1. Key Findings
5.2. Mammalian Cell Culture
5.3. Microbial Fermentation
6. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Indication
6.1. Key Findings
6.2. Cancer
6.3. Inflammation
6.4. Cardiovascular diseases
6.5. Transplant Rejection
6.6. Respiratory
6.7. Infectious diseases
7. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Technology Platforms
7.1. Key Findings
7.2. Transgenic-Mouse
7.3. Antibody Drug Conjugate
7.4. Phage-Display
8. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Target Mechanism of Action
8.1. Key Findings
8.2. CGRP
8.3. HER2
8.4. CTLA4
8.5. TNF alpha
8.6. EGFR
8.7. VEGF
8.8. Anti CD
8.9. Anti-IL
8.10. IgGs, PD-1/PD-L1
9. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Care Delivery Setting
9.1. Key Findings
9.2. Primary
9.3. Specialty Care
10. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Route of Administration
10.1. Key Findings
10.2. Subcutaneous
10.3. Intravenous
11. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Drug Types
11.1. Key Findings
11.2. Branded Biologics
11.3. Biosimilars
12. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Region
12.1. Key Findings
12.2. North America
12.2.1. U.S.
12.2.2. Canada
12.3. Europe
12.3.1. UK
12.3.2. Germany
12.3.3. Rest of Europe
12.4. Asia-Pacific
12.4.1. China
12.4.2. Japan
12.4.3. India
12.4.4. Rest of Asia-Pacific
12.5. Latin America
12.5.1. Brazil
12.5.2. Mexico
12.6. Middle East & Africa
12.6.1. South Africa
12.6.2. Rest of Middle East & Africa
13. Company Profiles
13.1. Pfizer, Inc.,
13.1.1. Overview
13.1.2. Financials
13.1.3. Product Benchmarking
13.1.4. Recent Developments
13.2. GlaxoSmithKline PLC
13.2.1. Overview
13.2.2. Financials
13.2.3. Product Benchmarking
13.2.4. Recent Developments
13.3. Novartis AG
13.3.1. Overview
13.3.2. Financials
13.3.3. Product Benchmarking
13.3.4. Recent Developments
13.4. Merck & Co., Inc.
13.4.1. Overview
13.4.2. Financials
13.4.3. Product Benchmarking
13.4.4. Recent Developments
13.5. Eli Lily & Co.
13.5.1. Overview
13.5.2. Financials
13.5.3. Product Benchmarking
13.5.4. Recent Developments
13.6. AstraZeneca
13.6.1. Overview
13.6.2. Financials
13.6.3. Product Benchmarking
13.6.4. Recent Developments
13.7. Amgen, Inc.
13.7.1. Overview
13.7.2. Financials
13.7.3. Product Benchmarking
13.7.4. Recent Developments
13.8. Abbott Laboratories
13.8.1. Overview
13.8.2. Financials
13.8.3. Product Benchmarking
13.8.4. Recent Developments
13.9. Thermo Fisher Scientific, Inc.
13.9.1. Overview
13.9.2. Financials
13.9.3. Product Benchmarking
13.9.4. Recent Developments
13.10. Bistro-Myers Squibb.
13.10.1. Overview
13.10.2. Financials
13.10.3. Product Benchmarking
13.10.4. Recent Developments
13.11. Mylan N.V.
13.11.1. Overview
13.11.2. Financials
13.11.3. Product Benchmarking
13.11.4. Recent Developments
13.12. Daiichi Sankyo Company, Ltd.
13.12.1. Overview
13.12.2. Financials
13.12.3. Product Benchmarking
13.12.4. Recent Developments
13.13. Bayer AG
13.13.1. Overview
13.13.2. Financials
13.13.3. Product Benchmarking
13.13.4. Recent Developments
13.14. Hoffmann-La Roche Ltd.
13.14.1. Overview
13.14.2. Financials
13.14.3. Product Benchmarking
13.14.4. Recent Developments
13.15. Novo Nordisk A/S
13.15.1. Overview
13.15.2. Financials
13.15.3. Product Benchmarking
13.15.4. Recent Developments